Vitamin C destroys aggressive Cancers when paired with THIS Easy Nutrition Protocol!

Scientific concepts, discoveries, and nature/health phenomena

1) Vitamin C + fasting-mimicking diet (FMD) selectively kills certain cancers

• A “massive study” tested isolated human cancer cells, followed by tumors in mice.
• Two main variables were compared:
  • Fasting-mimicking diet condition (a short-term calorie restriction pattern)
  • High-dose vitamin C
• Reported results:
  • Vitamin C + FMD conditions increased cancer cell death compared with control.
  • In some cases, the combination reached near-complete (“near 100%”) cancer cell killing in tested cancers.
  • The effects were reported across multiple cancer types (examples mentioned: colorectal, lung, pancreatic), though not universally across all tumors from the same organ region.

2) The effect depends on a specific genetic mutation (KRAS mutation)

A key “mystery” was that not all cancers responded.

• Some cancers showed strong killing with FMD + vitamin C, while others showed no effect.
• This difference was linked to a KRAS mutation (referred to as the “Kras mutation”).
• Summary logic:
  • KRAS-mutant cancers: susceptible to killing by FMD + vitamin C
  • Non-KRAS-mutant cancers: resistant (no cancer death observed in those comparisons)

3) Mechanism: vitamin C increases oxidative stress (not via antioxidant activity)

The study is described as challenging the usual expectation that vitamin C acts mainly as an antioxidant.

• Instead of neutralizing reactive species as the primary action:
  • Vitamin C is described as increasing damaging oxidizing molecules (i.e., oxidative stress) inside cancer cells.
• This oxidative increase is presented as a main reason cancer cells are harmed.

4) Mechanism: reduction of an iron-protecting protein increases damaging free iron

Researchers also reported a separate (or linked) mechanism involving iron handling.

• Vitamin C was described as reducing a protective protein called ferritin heavy chain.
• Ferritin heavy chain is described as binding iron.
• Proposed downstream effect:
  • Less ferritin heavy chain → more free iron inside the cancer cell
  • Free iron is described as highly damaging because it promotes oxidative damage

5) Translational claims and limitations

• The results are described as pre-clinical (cells/animals).
• The video claims:
  • A similar direction of results in mice
  • Some evidence exists in humans
• However, the speaker emphasizes that direct clinical trials of the exact combination are not yet established.
• No clinical trials for vitamin C + FMD were reported by the speaker at the time of the video, though trials were described as planned/underway.

6) Interaction with standard cancer treatment

The study is also described as testing a combination with a standard therapy.

• Tested condition:
  • FMD + vitamin C + a standard anti-cancer drug
• Reported outcome:
  • The combination was claimed to be more effective than without vitamin C/FMD.

---

Methodology/protocol shared in the subtitles (FMD + vitamin C)

Fasting-mimicking diet (FMD) schedule (as described)

• Duration: 5 days
• Calorie restriction targets:
  • Day 1: ~600 calories
  • Days 2–5 (next 4 days): ~300 calories/day
• Macro targets (approximate):
  • ~10% protein
  • ~45% carbohydrates
  • ~45% dietary fat
• Frequency:
  • Once per month, every month
• Diet type:
  • The original FMD is plant-based (as stated in the subtitles)

Vitamin C dosing notes (as described)

• The studies use very high doses (the speaker says “many grams”).
• Safety cautions mentioned:
  • GI distress
  • kidney stones
  • possible effects in people with conditions that increase iron absorption
  • interference with routine blood tests

---

Cancers/specific examples mentioned

The subtitles list examples of KRAS-mutant cancers (not all cancers are KRAS-mutant, per the speaker), including:

• colorectal adenocarcinomas
• pancreatic ductal adenocarcinomas
• small intestinal adenocarcinomas
• lung adenocarcinomas
• ovarian cancers

The speaker emphasizes non-universality:

• The same organ region can contain tumors with different KRAS mutation status, leading to different responses.

---

Researchers or sources featured (as stated in the subtitles)

• No specific researcher names, institutions, or journal citations are provided in the subtitles text.
• The speaker references “researchers” and “a massive study” but does not name the study authors or institutions.